Association between serum α1-antitrypsin levels and all-cause mortality in the general population: the Nagahama study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 08 2021
26 08 2021
Historique:
received:
26
01
2021
accepted:
17
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
9
11
2021
Statut:
epublish
Résumé
Circulating levels of inflammatory proteins have to be prognostic markers of all-cause mortality. α1-Antitrypsin (AAT) is a major inflammatory plasma protein, but its association with all-cause mortality is unclear. We aimed to evaluate the prognostic significance of AAT levels for all-cause mortality. Study participants comprised 9682 community residents (53.5 ± 13.3 years old). During the 9.8-year follow-up period, 313 participants died from any cause. The mortality rate increased linearly with AAT quintiles (Q1, 18.2; Q2, 24.7; Q3, 23.8; Q4, 31.9; Q5, 64.6 per 10,000 person-years). There were significant correlations between AAT and high-sensitivity C-reactive protein (hsCRP) levels (correlation coefficient, 0.331; P < 0.001). However, the Cox model analysis, when adjusted for possible covariates including hsCRP, identified the fifth AAT quintile as a risk factor for all-cause death (hazard ratio, 2.12 [95% confidence interval, 1.41-3.18]; P < 0.001). An analysis of participants older than 50 years (hazard ratio, 1.98, P < 0.001) yielded similar results. The hazard ratio increased proportionately in combination with high AAT and high hsCRP levels, and the highest hazard ratio reached 4.51 (95% confidence interval, 3.14-6.54, P < 0.001). High AAT levels were determined to be an independent risk factor for mortality in the general population.
Identifiants
pubmed: 34446826
doi: 10.1038/s41598-021-96833-3
pii: 10.1038/s41598-021-96833-3
pmc: PMC8390682
doi:
Substances chimiques
Biomarkers
0
alpha 1-Antitrypsin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17241Informations de copyright
© 2021. The Author(s).
Références
J Lab Precis Med. 2020 Apr;5:
pubmed: 32363327
Stroke. 2002 Dec;33(12):2744-9
pubmed: 12468764
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
J Urol. 2020 Nov;204(5):996-1002
pubmed: 32396408
Lancet. 2005 Jun 25-Jul 1;365(9478):2225-36
pubmed: 15978931
Nat Commun. 2015 Jul 15;6:7754
pubmed: 26174136
J Am Coll Cardiol. 2017 Aug 22;70(8):913-922
pubmed: 28818200
Hypertens Res. 2002 Nov;25(6):857-64
pubmed: 12484509
Lancet. 2010 Jan 9;375(9709):132-40
pubmed: 20031199
Circulation. 2004 Jul 6;110(1):27-31
pubmed: 15210605
PLoS One. 2015 Nov 23;10(11):e0143288
pubmed: 26599441
Hepatology. 1983 May-Jun;3(3):356-9
pubmed: 6601607
PLoS One. 2013 Apr 22;8(4):e62080
pubmed: 23630624
J Hypertens. 2018 Mar;36(3):587-593
pubmed: 29084086
PLoS Med. 2014 Feb 25;11(2):e1001606
pubmed: 24586121
J Am Coll Cardiol. 2007 May 29;49(21):2129-38
pubmed: 17531663
Clin Chem. 2015 May;61(5):714-23
pubmed: 25779987
Int J Epidemiol. 2006 Aug;35(4):922-31
pubmed: 16565153
J Intern Med. 2014 Oct;276(4):311-35
pubmed: 24661570
Circ Genom Precis Med. 2018 Nov;11(11):e002234
pubmed: 30571186
Circulation. 2002 Nov 12;106(20):2555-60
pubmed: 12427651
Atherosclerosis. 2016 Feb;245:171-80
pubmed: 26724527
Lancet Oncol. 2004 Mar;5(3):182-90
pubmed: 15003202
Circ Res. 2016 Apr 1;118(7):1106-15
pubmed: 26951635
Lancet. 2005 Dec 3;366(9501):1954-9
pubmed: 16325697
Circulation. 2002 Jun 4;105(22):2632-7
pubmed: 12045169
J Transl Med. 2017 Oct 27;15(1):219
pubmed: 29078787
Alcohol Clin Exp Res. 2014 Jun;38(6):1559-66
pubmed: 24749767
Diabetes. 2003 Feb;52(2):442-7
pubmed: 12540619
JAMA. 2018 Jul 17;320(3):272-280
pubmed: 29998297